Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland

Publisher Copyright: © 2022, The Author(s). By the end of July 2021, the majority of the Icelandic population had received vaccination against COVID-19. In mid-July a wave of SARS-CoV-2 infections, dominated by the Delta variant, spread through the population, followed by an Omicron wave in December...

Full description

Bibliographic Details
Published in:Nature Communications
Main Authors: Norddahl, Gudmundur L., Melsted, Páll, Gunnarsdottir, Kristbjorg, Halldórsson, Gísli Hreinn, Olafsdottir, Thorunn, Gylfason, Arnaldur, Kristjánsson, Már, Magnusson, Olafur T., sulem, patrick, Gudbjartsson, Daniel Fannar, Þorsteinsdóttir, Unnur, Jónsdóttir, Ingileif, Stefánsson, Kári
Other Authors: Faculty of Industrial Engineering, Mechanical Engineering and Computer Science, Office of Division of Clinical Services I, Other departments, Faculty of Medicine, Health Sciences, Landspitali - The National University Hospital of Iceland
Format: Article in Journal/Newspaper
Language:English
Published: 2022
Subjects:
Smitsjúkdómalæknisfræði
Angiotensin-Converting Enzyme 2
Antibodies
Viral/metabolism
BNT162 Vaccine
COVID-19/epidemiology
Humans
Iceland/epidemiology
RNA
Messenger
SARS-CoV-2/genetics
Vaccination
Vaccines
Synthetic
Viral Vaccines
mRNA Vaccines
Multidisciplinary
Physics and Astronomy (all)
Chemistry (all)
Biochemistry
Genetics and Molecular Biology (all)
Iceland
Online Access:https://hdl.handle.net/20.500.11815/3522
https://doi.org/10.1038/s41467-022-33076-4
Description
Summary:Publisher Copyright: © 2022, The Author(s). By the end of July 2021, the majority of the Icelandic population had received vaccination against COVID-19. In mid-July a wave of SARS-CoV-2 infections, dominated by the Delta variant, spread through the population, followed by an Omicron wave in December. A booster vaccination campaign was initiated to curb the spread of the virus. We estimate the risk of infection for different vaccine combinations using vaccination data from 276,028 persons and 963,557 qPCR tests for 277,687 persons. We measure anti-Spike-RBD antibody levels and ACE2-Spike binding inhibitory activity in 371 persons who received one of four recommended vaccination schedules with or without an mRNA vaccine booster. Overall, we find different antibody levels and inhibitory activity in recommended vaccination schedules, reflected in the observed risk of SARS-CoV-2 infections. We observe an increased protection following mRNA boosters, against both Omicron and Delta variant infections, although BNT162b2 boosters provide greater protection against Omicron than mRNA-1273 boosters. Peer reviewed

Similar Items